Based on the above, clinically defined HER2-positive subtype is not biologically homogeneous, and further studies are warranted to prospectively confirm that the ER and HER2 pathways engage in crosstalk and thereby synergize in tumor progression or differential sensitivity to therapies [38]. Here, ERBB2 is linked to neoplasm.